{"id":306,"date":"2019-12-08T22:15:32","date_gmt":"2019-12-09T03:15:32","guid":{"rendered":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/6-7-cardiac-glycosides\/"},"modified":"2022-12-13T16:25:20","modified_gmt":"2022-12-13T21:25:20","slug":"6-7-cardiac-glycosides","status":"publish","type":"chapter","link":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/6-7-cardiac-glycosides\/","title":{"raw":"6.7 Cardiac Glycosides","rendered":"6.7 Cardiac Glycosides"},"content":{"raw":"<h1>Cardiac Glycosides<\/h1>\r\n<h2>Digoxin<\/h2>\r\nDigoxin is a cardiac glycoside medication that has been used for centuries to treat heart failure. Currently it is the only positive inotropic drug we see in practice. It has three effects on heart muscle: positive inotropic action (increases contractility, stroke volume and, thus, cardiac output), negative chronotropic action (decreases heart rate), and negative dromotropic action (decrease conduction of cardiac cells). The inotropic effect of digoxin supports improving the heart's ability to pump with more strength, but it is important to understand that being on digoxin too long can actually cause more heart failure.\u00a0 Imagine that you have an elastic hairband; eventually, as you stretch it repeatedly over time, it either loses its elasticity or it breaks. The heart can only take so much force of contraction for so long before the stretch becomes exacerbated.\u00a0 Digoxin, although ground breaking for heart failure, should really be saved for use closer to end stage heart failure to support the heart in the final stages.[footnote]\r\n\r\nMcCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). <em>Pharmacology: A patient-centered nursing process approach.<\/em> pp. 443-454. Elsevier.[\/footnote]\r\n<h3>Mechanism of Action<\/h3>\r\nDigoxin works by inhibiting the sodium and potassium pump, which results in an increase in intracellular sodium and an influx of calcium into cardiac cells, causing the cardiac muscle fibers to contract more efficiently and increase cardiac output.[footnote]McCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). <em>Pharmacology: A patient-centered nursing process approach<\/em>. pp. 443-454. Elsevier.[\/footnote]\r\n<h3>Indications for Use<\/h3>\r\nThis medication is used as second-line treatment for clients who have heart failure or atrial fibrillation. Due to the risk for digoxin toxicity, the clinical use of digoxin has decreased and alternative, safer medications are being used. Also, remember that digoxin has an impact on the contractility of a heart, so this must be considered by the prescribing professionals.\r\n<h3>Nursing Considerations Across the Lifespan<\/h3>\r\nApical pulse should be taken for a full minute before administration of this medication. If the apical pulse is less than 60, the dose should be withheld and the prescribing provider notified.\r\n\r\nSerum digoxin levels should be monitored, with a normal therapeutic range from 0.8 to 2 ng\/mL.\r\n\r\nSerum potassium levels should also be closely monitored for clients on digoxin because hypokalemia increases the effect of digoxin and can result in digoxin toxicity. Normal potassium level is 3.5 to 5.0 mEq\/L, and a result less than 3.5 should be immediately reported to the provider.\r\n\r\nNurses should closely monitor signs of digoxin toxicity. Geriatric clients have an increased risk for developing digoxin toxicity. Digibind is used to treat digoxin toxicity.\r\n<h3>Adverse\/Side Effects<\/h3>\r\nOverdose or accumulation of digoxin causes digoxin toxicity. Signs and symptoms of digoxin toxicity are bradycardia (heart rate less than 60), nausea, vomiting, visual changes (halos), and arrhythmias. Cardiotoxicity is a serious adverse effect with ventricular dysrhythmias. Toxicity of this medication typically occurs at greater than 2 ng\/mL, but some clients may have signs and symptoms at lower levels. Pediatric clients typically present with bradycardia or arrhythmias if toxicity is occurring.\r\n\r\nDecreased renal function, hypokalemia, hypercalcemia, and hypomagnesemia may increase risk for digoxin toxicity.\r\n\r\nCommon side effects include GI symptoms, headache, weakness, dizziness, anxiety, depression, delirium, and hallucination.[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\"  rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\"  rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\"  rel=\"noopener noreferrer\">public domain<\/a>. [\/footnote]\r\n<h3>Client Teaching &amp; Education<\/h3>\r\nThe client should be instructed to follow the prescribed dosing regimen and take medications at the same time each day.\u00a0 The client should be cautious not to double up on medication doses.\u00a0 Additionally, the client should consult the healthcare provider for follow-up instruction if two or more doses of medication are missed.\r\n\r\nClients should receive education regarding pulse rate monitoring and report any pulse rate less than 60.\u00a0 If the client experiences signs of digoxin toxicity, this should be reported to the provider immediately.\u00a0 The medication should be stored in its original container and care should be taken not to mix the medication with other medications.[footnote]uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\"  rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]\u00a0\r\n<h1>Digoxin Medication Card<\/h1>\r\nNow let's take a closer look at the medication card for digoxin in Table 6.7.[footnote]This work is a derivative of\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\"  rel=\"noopener noreferrer\">Daily Med<\/a>\u00a0by\u00a0<a href=\"https:\/\/www.nlm.nih.gov\/\"  rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a>\u00a0in the<a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\"  rel=\"noopener noreferrer\">\u00a0public domain<\/a><span style=\"font-size: 12.8px;\">.[\/footnote]<\/span><span style=\"text-align: initial; font-size: 1em;\"> Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.\r\n<\/span>\r\n<div class=\"textbox textbox--learning-objectives\"><header class=\"textbox__header\">\r\n<h2 class=\"textbox__title\">Medication Card 6.7.1: Digoxin<\/h2>\r\n<\/header>\r\n<div class=\"textbox__content\">\r\n\r\n<strong>Class: <\/strong>Cardiac Glycosides\r\n\r\n<strong>Prototypes: <\/strong>Digoxin\r\n\r\n<strong>Mechanism: <\/strong>Digoxin works by inhibiting the sodium and potassium pump, which results in an increase in intracellular sodium and an influx of calcium into cardiac cells, causing the cardiac muscle fibers to contract more efficiently and increase cardiac output\r\n<h3>Therapeutic Effects<\/h3>\r\n<ul>\r\n \t<li>Increased pumping action increases in improved cardiac output<\/li>\r\n<\/ul>\r\n<h3>Administration<\/h3>\r\n<ul>\r\n \t<li>Typically given PO without food once a day in the morning<\/li>\r\n \t<li>Take within 2hrs pre or post eating high fiber foods for best absorption<\/li>\r\n \t<li>Take Antacids, metoclopramide as far from digoxin as possible<\/li>\r\n<\/ul>\r\n<h3>Indications<\/h3>\r\n<ul>\r\n \t<li>Heart failure<\/li>\r\n \t<li>Irregular heartbeat such as chronic atrial fibrillation<\/li>\r\n<\/ul>\r\n<h3>Contraindications<\/h3>\r\n<ul>\r\n \t<li>Kidney or hyper or hypo thyroid problems<\/li>\r\n \t<li>Avoid alcohol or driving machinery if this drug causes dizziness for the person<\/li>\r\n \t<li>Pregnancy-must talk with MD to take or not to take but it is possible<\/li>\r\n \t<li>It does cross into breast milk but no reported harm- talk with MD<\/li>\r\n \t<li>St Johns Wort, antifungals and some antibiotics can affect the removal of digoxin in the body<\/li>\r\n<\/ul>\r\n<h3>Side Effects<\/h3>\r\n<ul>\r\n \t<li>Digoxin toxicity; early signs include nausea, vomiting, and diarrhea<\/li>\r\n \t<li>Bradycardia and arrhythmias<\/li>\r\n \t<li>Headache, weakness, dizziness, and mental changes such as anxiety or hallucinations<\/li>\r\n \t<li>Gynecomastia (with prolonged use)<\/li>\r\n \t<li><strong>S<\/strong><strong>AFETY<\/strong><strong>: <\/strong>Geriatrics have increased risk of toxicity-Digibind is used to treat toxicity<\/li>\r\n<\/ul>\r\n<h3>Nursing Considerations<\/h3>\r\n<ul>\r\n \t<li>Apical pulse check for full 1 minute before administration<\/li>\r\n \t<li>Monitor serum digoxin levels for toxicity and potassium blood levels<\/li>\r\n \t<li>Monitor for blood pressure<\/li>\r\n \t<li>Signs and symptoms of heart failure and overload including urine output and respiratory assessment<\/li>\r\n<\/ul>\r\n<\/div>\r\n<\/div>\r\n<div class=\"textbox textbox--key-takeaways\"><header class=\"textbox__header\">Clinical Reasoning and Decision-Making Activities 6.7a\r\n<h2 style=\"word-spacing: 0px;\"><img class=\"alignright wp-image-50\" src=\"https:\/\/opentextbc.ca\/accessibilitytoolkit\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1.png\" alt=\"Image of lightbulb in a circle\" width=\"200\" height=\"200\" \/><\/h2>\r\n<\/header>\r\n<div class=\"textbox__content\">\r\n<ol>\r\n \t<li>Why should a nurse assess the apical pulse for 1 full minute before administering digoxin?<\/li>\r\n \t<li>How does a nurse evaluate whether digoxin is effective?<\/li>\r\n \t<li>Why must the nurse monitor serum potassium levels as well as digoxin levels?<\/li>\r\n \t<li>A nurse enters a patient\u2019s room and the patient complains \u201cMy vision seems strange and I feel nauseated.\u201d What is the nurse\u2019s next best action?<\/li>\r\n<\/ol>\r\nNote: Answers these questions can be found in the \"<a href=\"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/chapter-6-answer-key\/\">Answer Key<\/a>\" sections at the end of the book.\r\n\r\n<\/div>\r\n<\/div>\r\n<h2 style=\"text-align: left;\">Digibind<\/h2>\r\nDigibind is used to treat digoxin toxicity.\r\n<h3>Mechanism of Action<\/h3>\r\nDigibind binds to digoxin molecules, reducing free digoxin.\r\n<h3>Indications for Use<\/h3>\r\nThis medication is the antidote for digoxin. Digibind is administered when a patient is experiencing life-threatening digoxin toxicity.\r\n<h3>Nursing Considerations Across the Lifespan<\/h3>\r\nThere are no contraindications when using digibind.\r\n<h3>Adverse\/Side Effects<\/h3>\r\nThe most common effects a client may experience are worsening heart failure or atrial fibrillation, and hypokalemia.[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\"  rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\"  rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the<a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\"  rel=\"noopener noreferrer\"> public domain<\/a>.[\/footnote]\r\n<h3>Client Teaching &amp; Education<\/h3>\r\nThe client should report any signs of worsening heart failure, atrial fibrillation, or hypokalemia immediately to the healthcare provider.[footnote]uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\"  rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]","rendered":"<h1>Cardiac Glycosides<\/h1>\n<h2>Digoxin<\/h2>\n<p>Digoxin is a cardiac glycoside medication that has been used for centuries to treat heart failure. Currently it is the only positive inotropic drug we see in practice. It has three effects on heart muscle: positive inotropic action (increases contractility, stroke volume and, thus, cardiac output), negative chronotropic action (decreases heart rate), and negative dromotropic action (decrease conduction of cardiac cells). The inotropic effect of digoxin supports improving the heart&#8217;s ability to pump with more strength, but it is important to understand that being on digoxin too long can actually cause more heart failure.\u00a0 Imagine that you have an elastic hairband; eventually, as you stretch it repeatedly over time, it either loses its elasticity or it breaks. The heart can only take so much force of contraction for so long before the stretch becomes exacerbated.\u00a0 Digoxin, although ground breaking for heart failure, should really be saved for use closer to end stage heart failure to support the heart in the final stages.<a class=\"footnote\" title=\"McCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). Pharmacology: A patient-centered nursing process approach. pp. 443-454. Elsevier.\" id=\"return-footnote-306-1\" href=\"#footnote-306-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><\/p>\n<h3>Mechanism of Action<\/h3>\n<p>Digoxin works by inhibiting the sodium and potassium pump, which results in an increase in intracellular sodium and an influx of calcium into cardiac cells, causing the cardiac muscle fibers to contract more efficiently and increase cardiac output.<a class=\"footnote\" title=\"McCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). Pharmacology: A patient-centered nursing process approach. pp. 443-454. Elsevier.\" id=\"return-footnote-306-2\" href=\"#footnote-306-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><\/p>\n<h3>Indications for Use<\/h3>\n<p>This medication is used as second-line treatment for clients who have heart failure or atrial fibrillation. Due to the risk for digoxin toxicity, the clinical use of digoxin has decreased and alternative, safer medications are being used. Also, remember that digoxin has an impact on the contractility of a heart, so this must be considered by the prescribing professionals.<\/p>\n<h3>Nursing Considerations Across the Lifespan<\/h3>\n<p>Apical pulse should be taken for a full minute before administration of this medication. If the apical pulse is less than 60, the dose should be withheld and the prescribing provider notified.<\/p>\n<p>Serum digoxin levels should be monitored, with a normal therapeutic range from 0.8 to 2 ng\/mL.<\/p>\n<p>Serum potassium levels should also be closely monitored for clients on digoxin because hypokalemia increases the effect of digoxin and can result in digoxin toxicity. Normal potassium level is 3.5 to 5.0 mEq\/L, and a result less than 3.5 should be immediately reported to the provider.<\/p>\n<p>Nurses should closely monitor signs of digoxin toxicity. Geriatric clients have an increased risk for developing digoxin toxicity. Digibind is used to treat digoxin toxicity.<\/p>\n<h3>Adverse\/Side Effects<\/h3>\n<p>Overdose or accumulation of digoxin causes digoxin toxicity. Signs and symptoms of digoxin toxicity are bradycardia (heart rate less than 60), nausea, vomiting, visual changes (halos), and arrhythmias. Cardiotoxicity is a serious adverse effect with ventricular dysrhythmias. Toxicity of this medication typically occurs at greater than 2 ng\/mL, but some clients may have signs and symptoms at lower levels. Pediatric clients typically present with bradycardia or arrhythmias if toxicity is occurring.<\/p>\n<p>Decreased renal function, hypokalemia, hypercalcemia, and hypomagnesemia may increase risk for digoxin toxicity.<\/p>\n<p>Common side effects include GI symptoms, headache, weakness, dizziness, anxiety, depression, delirium, and hallucination.<a class=\"footnote\" title=\"This work is a derivative of Daily Med by U.S. National Library of Medicine in the public domain.\" id=\"return-footnote-306-3\" href=\"#footnote-306-3\" aria-label=\"Footnote 3\"><sup class=\"footnote\">[3]<\/sup><\/a><\/p>\n<h3>Client Teaching &amp; Education<\/h3>\n<p>The client should be instructed to follow the prescribed dosing regimen and take medications at the same time each day.\u00a0 The client should be cautious not to double up on medication doses.\u00a0 Additionally, the client should consult the healthcare provider for follow-up instruction if two or more doses of medication are missed.<\/p>\n<p>Clients should receive education regarding pulse rate monitoring and report any pulse rate less than 60.\u00a0 If the client experiences signs of digoxin toxicity, this should be reported to the provider immediately.\u00a0 The medication should be stored in its original container and care should be taken not to mix the medication with other medications.<a class=\"footnote\" title=\"uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral\" id=\"return-footnote-306-4\" href=\"#footnote-306-4\" aria-label=\"Footnote 4\"><sup class=\"footnote\">[4]<\/sup><\/a>\u00a0<\/p>\n<h1>Digoxin Medication Card<\/h1>\n<p>Now let&#8217;s take a closer look at the medication card for digoxin in Table 6.7.<a class=\"footnote\" title=\"This work is a derivative of\u00a0Daily Med\u00a0by\u00a0U.S. National Library of Medicine\u00a0in the\u00a0public domain.\" id=\"return-footnote-306-5\" href=\"#footnote-306-5\" aria-label=\"Footnote 5\"><sup class=\"footnote\">[5]<\/sup><\/a><\/span><span style=\"text-align: initial; font-size: 1em;\"> Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.<br \/>\n<\/span><\/p>\n<div class=\"textbox textbox--learning-objectives\">\n<header class=\"textbox__header\">\n<h2 class=\"textbox__title\">Medication Card 6.7.1: Digoxin<\/h2>\n<\/header>\n<div class=\"textbox__content\">\n<p><strong>Class: <\/strong>Cardiac Glycosides<\/p>\n<p><strong>Prototypes: <\/strong>Digoxin<\/p>\n<p><strong>Mechanism: <\/strong>Digoxin works by inhibiting the sodium and potassium pump, which results in an increase in intracellular sodium and an influx of calcium into cardiac cells, causing the cardiac muscle fibers to contract more efficiently and increase cardiac output<\/p>\n<h3>Therapeutic Effects<\/h3>\n<ul>\n<li>Increased pumping action increases in improved cardiac output<\/li>\n<\/ul>\n<h3>Administration<\/h3>\n<ul>\n<li>Typically given PO without food once a day in the morning<\/li>\n<li>Take within 2hrs pre or post eating high fiber foods for best absorption<\/li>\n<li>Take Antacids, metoclopramide as far from digoxin as possible<\/li>\n<\/ul>\n<h3>Indications<\/h3>\n<ul>\n<li>Heart failure<\/li>\n<li>Irregular heartbeat such as chronic atrial fibrillation<\/li>\n<\/ul>\n<h3>Contraindications<\/h3>\n<ul>\n<li>Kidney or hyper or hypo thyroid problems<\/li>\n<li>Avoid alcohol or driving machinery if this drug causes dizziness for the person<\/li>\n<li>Pregnancy-must talk with MD to take or not to take but it is possible<\/li>\n<li>It does cross into breast milk but no reported harm- talk with MD<\/li>\n<li>St Johns Wort, antifungals and some antibiotics can affect the removal of digoxin in the body<\/li>\n<\/ul>\n<h3>Side Effects<\/h3>\n<ul>\n<li>Digoxin toxicity; early signs include nausea, vomiting, and diarrhea<\/li>\n<li>Bradycardia and arrhythmias<\/li>\n<li>Headache, weakness, dizziness, and mental changes such as anxiety or hallucinations<\/li>\n<li>Gynecomastia (with prolonged use)<\/li>\n<li><strong>S<\/strong><strong>AFETY<\/strong><strong>: <\/strong>Geriatrics have increased risk of toxicity-Digibind is used to treat toxicity<\/li>\n<\/ul>\n<h3>Nursing Considerations<\/h3>\n<ul>\n<li>Apical pulse check for full 1 minute before administration<\/li>\n<li>Monitor serum digoxin levels for toxicity and potassium blood levels<\/li>\n<li>Monitor for blood pressure<\/li>\n<li>Signs and symptoms of heart failure and overload including urine output and respiratory assessment<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<div class=\"textbox textbox--key-takeaways\">\n<header class=\"textbox__header\">Clinical Reasoning and Decision-Making Activities 6.7a<\/p>\n<h2 style=\"word-spacing: 0px;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-50\" src=\"https:\/\/opentextbc.ca\/accessibilitytoolkit\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1.png\" alt=\"Image of lightbulb in a circle\" width=\"200\" height=\"200\" srcset=\"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1.png 300w, https:\/\/opentextbc.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1-150x150.png 150w, https:\/\/opentextbc.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1-65x65.png 65w, https:\/\/opentextbc.ca\/nursingpharmacology\/wp-content\/uploads\/sites\/397\/2019\/09\/ORN-Icons_lightbulb-300x300-1-225x225.png 225w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/h2>\n<\/header>\n<div class=\"textbox__content\">\n<ol>\n<li>Why should a nurse assess the apical pulse for 1 full minute before administering digoxin?<\/li>\n<li>How does a nurse evaluate whether digoxin is effective?<\/li>\n<li>Why must the nurse monitor serum potassium levels as well as digoxin levels?<\/li>\n<li>A nurse enters a patient\u2019s room and the patient complains \u201cMy vision seems strange and I feel nauseated.\u201d What is the nurse\u2019s next best action?<\/li>\n<\/ol>\n<p>Note: Answers these questions can be found in the &#8220;<a href=\"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/chapter-6-answer-key\/\">Answer Key<\/a>&#8221; sections at the end of the book.<\/p>\n<\/div>\n<\/div>\n<h2 style=\"text-align: left;\">Digibind<\/h2>\n<p>Digibind is used to treat digoxin toxicity.<\/p>\n<h3>Mechanism of Action<\/h3>\n<p>Digibind binds to digoxin molecules, reducing free digoxin.<\/p>\n<h3>Indications for Use<\/h3>\n<p>This medication is the antidote for digoxin. Digibind is administered when a patient is experiencing life-threatening digoxin toxicity.<\/p>\n<h3>Nursing Considerations Across the Lifespan<\/h3>\n<p>There are no contraindications when using digibind.<\/p>\n<h3>Adverse\/Side Effects<\/h3>\n<p>The most common effects a client may experience are worsening heart failure or atrial fibrillation, and hypokalemia.<a class=\"footnote\" title=\"This work is a derivative of Daily Med by U.S. National Library of Medicine in the public domain.\" id=\"return-footnote-306-6\" href=\"#footnote-306-6\" aria-label=\"Footnote 6\"><sup class=\"footnote\">[6]<\/sup><\/a><\/p>\n<h3>Client Teaching &amp; Education<\/h3>\n<p>The client should report any signs of worsening heart failure, atrial fibrillation, or hypokalemia immediately to the healthcare provider.<a class=\"footnote\" title=\"uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral\" id=\"return-footnote-306-7\" href=\"#footnote-306-7\" aria-label=\"Footnote 7\"><sup class=\"footnote\">[7]<\/sup><\/a><\/p>\n<hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-306-1\">\r\n\r\nMcCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). <em>Pharmacology: A patient-centered nursing process approach.<\/em> pp. 443-454. Elsevier. <a href=\"#return-footnote-306-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-306-2\">McCuistion, L., Vuljoin-DiMaggio, K., Winton, M, &amp; Yeager, J. (2018). <em>Pharmacology: A patient-centered nursing process approach<\/em>. pp. 443-454. Elsevier. <a href=\"#return-footnote-306-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><li id=\"footnote-306-3\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" rel=\"noopener noreferrer\">public domain<\/a>.  <a href=\"#return-footnote-306-3\" class=\"return-footnote\" aria-label=\"Return to footnote 3\">&crarr;<\/a><\/li><li id=\"footnote-306-4\">uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a> <a href=\"#return-footnote-306-4\" class=\"return-footnote\" aria-label=\"Return to footnote 4\">&crarr;<\/a><\/li><li id=\"footnote-306-5\">This work is a derivative of\u00a0<a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" rel=\"noopener noreferrer\">Daily Med<\/a>\u00a0by\u00a0<a href=\"https:\/\/www.nlm.nih.gov\/\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a>\u00a0in the<a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" rel=\"noopener noreferrer\">\u00a0public domain<\/a><span style=\"font-size: 12.8px;\">. <a href=\"#return-footnote-306-5\" class=\"return-footnote\" aria-label=\"Return to footnote 5\">&crarr;<\/a><\/li><li id=\"footnote-306-6\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" rel=\"noopener noreferrer\">Daily Med<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the<a class=\"internal\" href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" rel=\"noopener noreferrer\"> public domain<\/a>. <a href=\"#return-footnote-306-6\" class=\"return-footnote\" aria-label=\"Return to footnote 6\">&crarr;<\/a><\/li><li id=\"footnote-306-7\">uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a> <a href=\"#return-footnote-306-7\" class=\"return-footnote\" aria-label=\"Return to footnote 7\">&crarr;<\/a><\/li><\/ol><\/div>","protected":false},"author":90,"menu_order":7,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[50],"contributor":[],"license":[],"class_list":["post-306","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":268,"_links":{"self":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/users\/90"}],"version-history":[{"count":6,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/306\/revisions"}],"predecessor-version":[{"id":1468,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/306\/revisions\/1468"}],"part":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/268"}],"metadata":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/306\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/media?parent=306"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=306"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/contributor?post=306"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/opentextbc.ca\/nursingpharmacology\/wp-json\/wp\/v2\/license?post=306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}